A new door opens, but it is essential to accumulate further clinical evidence to control heart failure in diabetes with preserved ejection fraction

por Kashiwagi, Atsunori
Publicado 2019

Metabolic and hemodynamic effects of sodium‐dependent glucose cotransporter 2 inhibitors on cardio‐renal protection in the treatment of patients with type 2 diabetes mellitus

por Kashiwagi, Atsunori, Maegawa, Hiroshi
Publicado 2017

Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients

por Kashiwagi, Atsunori, Araki, Shinchi, Maegawa, Hiroshi
Publicado 2020

Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabe...

por Kashiwagi, Atsunori, Kazuta, Kenichi, Yoshida, Satoshi, Nagase, Itsuro
Publicado 2013

Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan

por Yasuda, Hitoshi, Hotta, Nigishi, Nakao, Kazuwa, Kasuga, Masato, Kashiwagi, Atsunori, Kawamori, Ryuzo
Publicado 2011

Evaluation of insulin regimens as an effective option for glycemic control in patients with type 2 diabetes: A propensity score‐matched cohort study across Japan (JDDM31)

por Kanatsuka, Azuma, Sato, Yasunori, Kawai, Koichi, Hirao, Koichi, Kobayashi, Masashi, Kashiwagi, Atsunori
Publicado 2014

Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32)

por Oishi, Mariko, Yamazaki, Katsuya, Okuguchi, Fuminobu, Sugimoto, Hidekatsu, Kanatsuka, Azuma, Kashiwagi, Atsunori
Publicado 2013

Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibit...

por Kashiwagi, Atsunori, Shoji, Shingo, Onozawa, Satoshi, Kosakai, Yoshinori, Waratani, Miina, Ito, Yuichiro
Publicado 2022

Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A...

por Kashiwagi, Atsunori, Shoji, Shingo, Kosakai, Yoshinori, Koga, Tadashi, Asakawa, Keiko, Rokuda, Mitsuhiro
Publicado 2022

Serum Concentrations of Trace Elements in Patients with Crohn’s Disease Receiving Enteral Nutrition

por Johtatsu, Tomoko, Andoh, Akira, Kurihara, Mika, Iwakawa, Hiromi, Tsujikawa, Tomoyuki, Kashiwagi, Atsunori, Fujiyama, Yoshihide, Sasaki, Masaya
Publicado 2007

Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Su...

por Yokoyama, Hiroki, Hirao, Koichi, Yamaguchi, Kohei, Oishi, Mariko, Lee, Gendai, Yagi, Noriharu, Takamura, Hiroshi, Kashiwagi, Atsunori
Publicado 2014

Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials

por Kashiwagi, Atsunori, Shestakova, Marina V., Ito, Yuichiro, Noguchi, Masahiro, Wilpshaar, Wim, Yoshida, Satoshi, Wilding, John P. H.
Publicado 2019

Prognostic Value of Gated Myocardial Perfusion Imaging for Asymptomatic Patients With Type 2 Diabetes: The J-ACCESS 2 investigation

por Yamasaki, Yoshimitsu, Nakajima, Kenichi, Kusuoka, Hideo, Izumi, Tohru, Kashiwagi, Atsunori, Kawamori, Ryuzo, Shimamoto, Kazuaki, Yamada, Nobuhiro, Nishimura, Tsunehiko
Publicado 2010

Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52‐week, open‐label study

por Yasuda, Hitoshi, Hotta, Nigishi, Kasuga, Masato, Kashiwagi, Atsunori, Kawamori, Ryuzo, Yamada, Tadaaki, Baba, Yuko, Alev, Levent, Nakajo, Ko
Publicado 2015

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials

por Kashiwagi, Atsunori, Yoshida, Satoshi, Nakamura, Ichiro, Kazuta, Kenichi, Ueyama, Eiji, Takahashi, Hideyuki, Satomi, Hayato, Kosakai, Yoshinori, Kawamuki, Kosei
Publicado 2016

Predictive Effects of Urinary Liver-Type Fatty Acid–Binding Protein for Deteriorating Renal Function and Incidence of Cardiovascular Disease in Type 2 Diabetic Patients Without Adv...

por Araki, Shin-ichi, Haneda, Masakazu, Koya, Daisuke, Sugaya, Takeshi, Isshiki, Keiji, Kume, Shinji, Kashiwagi, Atsunori, Uzu, Takashi, Maegawa, Hiroshi
Publicado 2013

Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus

por Sawaguchi, Makoto, Araki, Shin‐ichi, Kobori, Hiroyuki, Urushihara, Maki, Haneda, Masakazu, Koya, Daisuke, Kashiwagi, Atsunori, Uzu, Takashi, Maegawa, Hiroshi
Publicado 2012

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes

por Kashiwagi, Atsunori, Kadowaki, Takashi, Tajima, Naoko, Nonaka, Kenji, Taniguchi, Tadaaki, Nishii, Mikio, Ferreira, Juan Camilo Arjona, Amatruda, John M
Publicado 2011

Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014

por Kume, Shinji, Araki, Shin‐ichi, Ugi, Satoshi, Morino, Katsutaro, Koya, Daisuke, Nishio, Yoshihiko, Haneda, Masakazu, Kashiwagi, Atsunori, Maegawa, Hiroshi
Publicado 2019

Evaluation of a Novel Glucose Area Under the Curve (AUC) Monitoring System: Comparison with the AUC by Continuous Glucose Monitoring

por Ugi, Satoshi, Maegawa, Hiroshi, Morino, Katsutaro, Nishio, Yoshihiko, Sato, Toshiyuki, Okada, Seiki, Kikkawa, Yasuo, Watanabe, Toshihiro, Nakajima, Hiromu, Kashiwagi, Atsunori
Publicado 2016